Cancer Clinical Trials:
Glioblastoma Protocols

LS-P-CENTRIC: Cilengitide for subjects with newly diagnosed GBM and methylated MGMT gene promoter – a multicenter, open-label, controlled Phase III study, testing cilengitide in combination with standart treatment (tem with concomitant radiation theraphy, following by tem maintenance therapy) vs. standard treatment alone
Principal Investigator: Suriya Jeyapalan, MD
Sites: Rhode Island Hospital

RTOG 0825: Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma.
Principal Investigator: Brigid O’Connor, MD, PhD
Site: Rhode Island Hospital

RTOG 0929: A Randomized Phase I/II Study of ABT-888 in Combination with Temozolomide in Recurrent (Temozolomide Resistant)
Principal Investigator: Heinrich Elinzano, MD
Sites: Rhode Island Hospital

For more information about these clinical trials and how to participate, please call 401-444-HOPE (4673). For general information about clinical trials please visit the National Cancer Institute.